Alfasigma pays $300 million upfront to GSK for worldwide rights to linerixibat, an IBAT inhibitor for cholestatic pruritus in primary biliary cholangitis (PBC).
Total deal value up to $690M, including $100M on US approval, $20M on EU/UK approvals, and up to $270M in sales milestones, plus royalties.13
FDA decision expected March 24, 2026; also under review in EU, UK, China, Canada.134
Phase 3 GLISTEN trial met primary endpoint of itch reduction over 24 weeks vs placebo.24
GSK to focus on other liver programs like bepirovirsen and efimosfermin alfa; Alfasigma leverages hepatology expertise.15
Announced around March 9, 2026.6
Sources:
1. https://pharmaphorum.com/news/alfasigma-licenses-liver-drug-gsk-590m-deal
2. https://www.pharmaceutical-technology.com/newsletters/gsk-sells-liver-disease-drug-candidate-to-alfasigma-for-690m/
3. https://www.fiercebiotech.com/biotech/alfasigma-pens-690m-deal-gsk-itching-drug-awaiting-fda-approval-decision
4. https://european-biotechnology.com/latest-news/alfasigma-bets-up-to-690m-on-gsks-late-stage-pbc-itch-drug-ahead-of-fda-decision/
5. https://www.gsk.com/en-gb/media/press-releases/gsk-and-alfasigma-announce-agreement/
6. https://www.aol.com/articles/gsk-licenses-liver-disease-drug-074030677.html